APA (7th ed.) Citation

Hubalewska-Dydejczyk, A., Decristoforo, C., Mikolajczak, R., Kolenc, P., Opalinska, M., Garnuszek, P., . . . Lezaic, L. (2026). Improving the Somatostatin Receptor Status Assessment for Personalized and Precise Management of Neuroendocrine Neoplasms with the Use of a 99mTc-Radiolabeled Somatostatin Receptor Antagonist: The Final Results of the ERA PerMed TECANT Clinical Trial. Journal of Nuclear Medicine, 67(6), 895. https://doi.org/10.2967/jnumed.125.270347

Chicago Style (17th ed.) Citation

Hubalewska-Dydejczyk, Alicja, et al. "Improving the Somatostatin Receptor Status Assessment for Personalized and Precise Management of Neuroendocrine Neoplasms with the Use of a 99mTc-Radiolabeled Somatostatin Receptor Antagonist: The Final Results of the ERA PerMed TECANT Clinical Trial." Journal of Nuclear Medicine 67, no. 6 (2026): 895. https://doi.org/10.2967/jnumed.125.270347.

MLA (9th ed.) Citation

Hubalewska-Dydejczyk, Alicja, et al. "Improving the Somatostatin Receptor Status Assessment for Personalized and Precise Management of Neuroendocrine Neoplasms with the Use of a 99mTc-Radiolabeled Somatostatin Receptor Antagonist: The Final Results of the ERA PerMed TECANT Clinical Trial." Journal of Nuclear Medicine, vol. 67, no. 6, 2026, p. 895, https://doi.org/10.2967/jnumed.125.270347.